BIONTECH - BNTX STOCK NEWS

Pfizer (NYSE: PFE) and BioNTech (Nasdaq: BNTX) announced the U.S. government's purchase of an additional 200 million doses of their COVID-19 vaccine. This increases the total to 500 million doses under their supply agreement. The companies plan to deliver 110 million doses by December 31, 2021, and the remaining doses by April 30, 2022. The U.S. government will continue to provide the vaccine for free. The vaccine remains under Emergency Use Authorization and is aimed at preventing COVID-19.

Pfizer and BioNTech have signed a letter of intent with The Biovac Institute to manufacture and distribute their COVID-19 vaccine in Africa. This partnership aims to enhance vaccine access within the African Union, with production expected to exceed 100 million doses annually once fully operational. Technical transfer and equipment installations are set to begin immediately, with finished dose manufacturing commencing in 2022. Both companies continue to prioritize equitable vaccine distribution globally, committing to provide 2 billion doses to low and middle-income countries in 2021 and 2022.

Pfizer (NYSE: PFE) and BioNTech (Nasdaq: BNTX) have signed a letter of intent with The Biovac Institute to manufacture and distribute the Pfizer-BioNTech COVID-19 Vaccine in Africa. Biovac will join Pfizer's global supply chain, enhancing production capabilities across three continents with over 20 facilities. Production is set to begin in 2022, aiming for more than 100 million doses annually for the African Union. This collaboration underscores Pfizer's commitment to equitable vaccine access and explores further partnerships in Latin America.

BioNTech has announced its acquisition of Kite's individualized solid tumor neoantigen TCR cell therapy research and clinical manufacturing facility in Gaithersburg, MD. This deal enhances BioNTech's cell therapy pipeline and expands its manufacturing capabilities in North America, expected to close by the end of July 2021. With this acquisition, BioNTech aims to accelerate development in individualized cancer therapies while offering employment to all Kite employees at the facility. Financial terms were not disclosed.

BioNTech has entered into a purchase agreement to acquire Kite's solid tumor neoantigen T cell receptor R&D platform and clinical manufacturing facility in Gaithersburg, MD. This facility will bolster BioNTech's capabilities in developing individualized cancer therapies, complementing its existing infrastructure in Germany. Kite will receive an undisclosed upfront payment. The acquisition aims to enhance BioNTech's pipeline, which includes CAR-T therapies. All Kite Gaithersburg employees will be offered employment with BioNTech, indicating a commitment to further investment in the facility.

BioNTech has commenced its Phase 2 clinical trial for cancer vaccine candidate BNT111, targeting melanoma patients who are anti-PD1-refractory. This trial follows promising Phase 1 results demonstrating a favorable safety profile and durable responses. A total of 120 patients will be enrolled across clinical sites in the EU, UK, US, and Australia. The trial evaluates the efficacy of BNT111 in combination with Libtayo, aiming for a robust immune response against cancer.

On June 10, 2021, Pfizer and BioNTech announced a deal with the U.S. government to supply 500 million doses of their COVID-19 vaccine at a not-for-profit price. The agreement includes 200 million doses in 2021 and 300 million doses in the first half of 2022, aimed at low- and middle-income countries via the COVAX Facility. This initiative is part of their commitment to provide two billion doses globally over 18 months. The deliveries will support equitable vaccine access, with production centered in U.S. facilities.

Pfizer (PFE) and BioNTech (BNTX) announced a plan to provide 500 million COVID-19 vaccine doses to the U.S. government at a not-for-profit price, aimed at supporting global vaccination efforts. This includes 200 million doses by the end of 2021 and 300 million in early 2022. The U.S. government will donate these doses to low- and lower-middle-income countries through COVAX. Pfizer and BioNTech aim to produce up to 3 billion doses in 2021, enhancing their supply chain capabilities. Deliveries will begin in August 2021.

Pfizer and BioNTech announced an expansion of the Conditional Marketing Authorization (CMA) for COMIRNATY® in the EU to include adolescents aged 12 to 15. This follows a favorable opinion from the EMA's CHMP. The CMA is now valid across all 27 EU member states. Based on a Phase 3 trial of 2,260 participants, COMIRNATY® showed 100% efficacy in this age group with a favorable safety profile. Pfizer and BioNTech also plan to submit for Emergency Use Authorization for younger age cohorts later this year.